Imugene Limited
Biotechnology Research • 
Sydney, New South Wales, Australia • 21-50 Employees
Company overview
| Headquarters | 37 Bligh St, Suite 1006, Level 10, Sydney, New South Wales 2000, AU |
| Phone number | +6199009179551 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Biotechnology, Drug Development, Biotech, Immunotherapy, Cancer Vaccines, Immuno-Oncology, Immune System, Cancer Therapy, Her-2+ Cancers, Mimotopes, B-Cell Peptide Vaccines, B-Cell Vaccine Technology, Pd-1, B-Cell, Cancer Experts, Immune Checkpoint Inhibitor Monoclonal Antibodies |
| Founded | 2013 |
| Employees | 21-50 |
| Socials |
Key Contacts at Imugene Limited
Sharon Yavrom
Executive Director, Clinical Science
Leslie Chong
Chief Executive Officer & Managing Director
Monica Eris
Senior Director, Head Of Clinical Supply Chain, Logistics & Cmo Management
Vladimir Senyukov
Director, Cell Therapy
Grey A. Wilkinson
Senior Director - Translational Research
Michael Sadick
Senior Director Of Cmc Analytical Development
Amanda Seiz
Sr. Director, Project Management
Yuni Kim
Director Of Clinical Operations
Ralph Gill
Director Of Information Technology
Imugene Limited Email Formats
Imugene Limited uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@imugene.com), used 82.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@imugene.com | 82.6% |
{first initial}{last name} | jdoe@imugene.com | 17.4% |
About Imugene Limited
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets. ASX: IMU
Imugene Limited revenue & valuation
| Annual revenue | $27,148 |
| Revenue per employee | $1,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $86,873 |
| Total funding | $57,200,000 |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Imugene Limited has 12 employees across 7 departments.
Departments
Number of employees
Funding Data
Explore Imugene Limited's funding history, including investment rounds, total capital raised, and key backers.
Imugene Limited Tech Stack
Discover the technologies and tools that power Imugene Limited's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Security
Form builders
JavaScript libraries
Maps
JavaScript libraries
CDN
Web servers
JavaScript libraries
Programming languages
Security
South Africa
Korea, Republic of
New Zealand
Frequently asked questions
4.8
40,000 users
